The positive response to multiple ALKis of a NSCLC patient carrying a new and rare SPECCL1::ALK fusion serves as a reference for further clinical treatment and encourages the use of both AMP-NGS and in silico protein prediction models to discover and study the oncogenic potential of understudied and rare, potentially druggable ALK fusion variants. Here, ALK is linked to non-small cell lung carcinoma.